Skip to content

Prevention and treatment of kidney transplantation rejection by means of innovative therapeutic apheresis. - ND

Prevention and treatment of kidney transplantation rejection by means of innovative therapeutic apheresis. - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-007047-13-IT
Enrollment
Unknown
Registered
2009-03-30
Start date
2009-04-27
Completion date
Unknown
Last updated
2014-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients waiting for first corpse kidney transplantation or re-transplantation, with PRA values > 50% MedDRA version: 9.1 Level: LLT Classification code 10023439 Term: Kidney transplant rejection

Interventions

Sponsors

OSPEDALE POLICLINICO S. MATTEO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients of 18-70 years old; Patients in emodialysis suitable for kidney transplantation; patients with PRA > 50%; absence of active infections and procalcitonine in the normality ranges; absence of neoplastic processes; absence of active heart diseases; signed informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Absence of one of the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Main Objective: To prevent acute rejection in subjects waiting for first corpse kidney transplantation or re-transplantation.;Secondary Objective: Monitor of patients with signs of rejection.;Primary end point(s): Stabilize the PRA (Panel Reactive Antibodies)value below 10%

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026